A | B | C | D | E | F | |
---|---|---|---|---|---|---|
1 | Biomarkers of Aging | |||||
2 | Change with Age | Name | Marker | Mechanism of action | Clinical research method | Type specimen |
3 | decrease | high-density lipoprotein | general, aging, risk of cardiovascular disease | HDL activate the enzyme system in the liver, and antiatherogenic effect of HDL is due to their ability to transport cholesterol from the cells of the peripheral organs (including the vessels of the heart, arteries, brain, etc.) to the liver, where cholesterol is converted into bile acids and excreted. | homogeneous enzymatic colorimetric test (mmol / L) | blood serum |
4 | increase | low-density lipoprotein | aging, the risk of cardiovascular disease | We prove a direct link between high cholesterol levels and progressive formation of atherosclerotic plaques in the blood vessels, especially in the coronary arteries, which is the reason of having a coronary heart disease. | calculated by Friedewald formula (mmol / L) | blood serum |
5 | increase | very low density lipoproteins | enzymatic (CHOD-PAP) | blood serum | ||
6 | increase | ratio of low-density lipoprotein / LDL cholesterol | General | We prove a direct link between high cholesterol levels and progressive formation of atherosclerotic plaques in the blood vessels, especially in the coronary arteries, which is the reason of having a coronary heart disease. | calculation (E) | blood serum |
7 | increase | Total cholesterol (the husband) | Potential aging | We prove a direct link between high cholesterol levels and progressive formation of atherosclerotic plaques in the blood vessels, especially in the coronary arteries, which is the reason of having a coronary heart disease. | enzymatic (CHOD-PAP) (mmol / L) | blood serum |
8 | increase | total cholesterol | aging, the risk of cardiovascular disease | We prove a direct link between high cholesterol levels and progressive formation of atherosclerotic plaques in the blood vessels, especially in the coronary arteries, which is the reason of having a coronary heart disease. | enzymatic (CHOD-PAP) (mmol / L) | blood serum |
9 | increase | Triglycerides | general, the aging, the risk of coronary and peripheral atherosclerosis | homogeneous enzymatic colorimetric test (mmol / L) | blood serum | |
10 | decrease | ratio of triglyceride / high-density cholesterol | General | calculation (E) | blood serum | |
11 | decrease | apolipoprotein A1 | General, aging, atherosclerosis | Immunoturbidimetric (mg / dL) | blood serum | |
12 | increase | In apolipoprotein | aging, atherosclerosis | Immunoturbidimetric (mg / dL) | blood serum | |
13 | decrease | apolipoprotein E | Aging, Alzheimer's disease | (Mg / dl) | blood serum | |
14 | increase | ratio of apo B / apo A1 | General | payment (s) | blood serum | |
15 | increase | Circulating fatty acids | blood serum | |||
16 | decrease | phospholipids blood | General | Enzymatic determination of | blood serum | |
17 | increase | Adiponectin (husband) | Potential aging | correlate with the risk of myocardial infarction in men | enzyme multiplied immunoassay | blood serum |
18 | increase | lipofuscin | Potential aging | accumulates in cells during aging | autofluorescence detection of lipofuscin | blood plasma (with heparin and sodium fluoride as an inhibitor of glycolysis) |
19 | Increase / Decrease | Glucose | general, aging, diabetes mellitus type I and II | reflects the status of carbohydrate metabolism | glucose oxidase (GOD-PAP) (mmol / L) | blood plasma (with heparin and sodium fluoride as an inhibitor of glycolysis) |
20 | decrease | Glucose in the urine | General, aging, diabetes | When the concentration of glucose in the blood over 8,8-9,9 mmol / L higher than the maximum capacity of the kidneys to the reverse suction NIJ glucose (renal threshold), or reducing this ability due to changes in renal tubular function, glucose appears in the urine - is observed glycosuria . With age, the renal threshold for glucose is reduced. | hexokinase (mg / day) | urine |
21 | decrease | Glucose-tolerance test | Potential aging, diabetes | determination of glucose in the blood before and after sugar load. | glucose oxidase (GOD-PAP) (%) | blood plasma |
22 | increase | The end products of non-enzymatic glycosylation | Aging | formed during hyperglycemia | blood serum | |
23 | increase | Receptors of the end products of non-enzymatic glycosylation | Aging | hyperglycemia stimulates RKPG | blood serum | |
24 | increase | Pentosidine | aging, diabetes neinsulinzavisimogo | HPLC | blood serum | |
25 | increase | Albumin | aging, common, chronic liver disease, serdchnaya nedosttochnost, rheumatism | colorimetry (with bromocresol green) (g / l) | blood serum | |
26 | decrease | ratio of albumin / globulin blood | General, inflammation | inflammatory processes in the ratio decreases | blood serum | |
27 | decrease | Alpha-1-acid glycoprotein | General, inflammation | Inflammation | blood serum | |
28 | decrease | Alpha -1 microglobulin | kidney damage | blood serum | ||
29 | increase | Alpha-2-macroglobulin | General, inflammation | Inflammation | blood serum | |
30 | increase | beta2-microglobulin | tumor | blood serum | ||
31 | increase | Antistreptolysin-O | Rheumatic diseases | blood serum | ||
32 | increase | Atrial natriuretic peptide | Heart failure | Increases in tension fibrillation | fluorescent immunoassay | blood |
33 | increase | Brain natriuretic peptide-uretichesky | Heart failure | immunochromatography (pg / ml) | blood | |
34 | increase | Hepatocuprein | General inflammation, rheumatoid arthritis | copper content in the body | immunoturbidimetry (mg / ml) | blood serum |
35 | increase | C-natriuretic peptide | Heart failure | markers of the functional state of the contractile capacity of the heart muscle | blood serum | |
36 | increase | Eosinophilic cationic protein | General, inflammation | Inflammation | immunoassay | plasma |
37 | decrease | Ferritin | general, aging potential, a differential marker of anemia, cancer, inflammatory diseases | immunoassay (ug / L) | blood serum | |
38 | decrease | Fructosamine | General | indicator of blood glucose | colorimetry (nitro blue tetrazolium) (mmol / L) | blood serum |
39 | decrease | Globulin | General | blood serum | ||
40 | decrease | Glycosylated hemoglobin | Aging, diabetes | shows what was the concentration of glucose for 4-8 weeks prior to the study | cation exchange chromatography, high pressure (% of total hemoglobin) | blood |
41 | decrease | Haptoglobin | Inflammation, hemolysis | Acute inflammation and intravascular hemolysis | immunoturbidimetry (mg / l) | blood plasma, blood serum |
42 | decrease | Hemoglobin | General | colorimetry (g / l) | blood serum | |
43 | (decrease in multiple sclerosis) | Homocysteine | general, aging, atherosclerosis, thrombosis, diabetes, Alzheimer's disease | in higher concentrations is cytotoxic | immunosorbent assay (mmol / l) | blood plasma, blood serum |
44 | decrease | the average concentration of hemoglobin | General | Calculated by dividing the concentration of hemoglobin (in g/100 ml) in hematocrit, and multiplying by 100. | whole blood | |
45 | increase | Microalbumin | Kidney damage, diabetes | gets into the urine with kidney damage | immunoturbidimetry (mg / l) | urine |
46 | decrease | Myelin basic protein | damaged nervous tissue, tumors, stroke | marker of brain tissue damage | radioimmunoassay | spinal fluid |
47 | Increase / Decrease | Osteocalcin | Osteoporosis | formed during the formation of bone tissue | hemilyuministsentny "sandwich" 2-Site immunoassay specific for intact osteocalcin (1 - 49) and the fragment (1 - 43) (ng / ml) | blood serum |
48 | increase | Total protein in the urine | Common, kidney damage | colorimetry, turbidimetry, diagnostic strips (g / d) | urine | |
49 | decrease | Total protein in serum | general | azotometricheskie; gravimetric (weight), "pretsipitatsionnye"; spectrophotometric; Refractometric, colorimetric (g / l) | blood serum | |
50 | increase | Rheumatoid factor | Autoimmune diseases | nephelometry, turbidimetry, immunofluorescence (IU / ml) | blood serum | |
51 | decrease | Proteinogram (protein fractions) | General, inflammation | electrophoresis | blood serum | |
52 | decrease | Globulin, sex hormone binding | General | blood serum | ||
53 | increase | Thyroglobulin | Thyroid function | into the blood in the destruction of the thyroid cells | Immunoassay (ng / ml) | blood serum |
54 | decrease | Transferrin | inflammation, tumor | immunoturbidimetry (g / l) | blood serum | |
55 | increase | Troponin I | heart disease, heart attack | into the blood in the destruction of cells | immunochromatography, immunohemilyuminestsentny analysis (ng / ml) | blood |
56 | increase | Troponin P | heart disease, heart attack | into the blood in the destruction of cells | immunochromatography, immunohemilyuminestsentny analysis | blood |
57 | increase | Myoglobin | damaged muscle tissue | into the blood in the destruction of cells | immunochromatography, immunohemilyuminestsentny analysis | blood |
58 | increase | Troponin T | myocardial | into the blood in the destruction of cells | reflectance photometry (ng / ml) | whole blood with heparin |
59 | increase | endothelin | Heart failure | Immunosorbent assay (pg / mol) | blood | |
60 | increase | Big-endothelin | Heart failure | Immunosorbent assay (pg / mol) | blood | |
61 | increase | C-reactive protein | aging, inflammation, rheumatoid diseases, tumors | Inflammation | Immunoturbidimetric (mg / l) | blood plasma |
62 | decrease | Immunoglobulin IgA | Aging | Inflammation | immunoassay (g / l) | blood plasma |
63 | decrease | Immunoglobulin IgG | Aging | Inflammation | immunoassay (g / l) | blood plasma |
64 | decrease | Immunoglobulin IgE | Aging | Inflammation | immunoassay (kU / L) | blood plasma |
65 | increase | Immunoglobulin IgM | Aging | Allergy | immunoassay (g / l) | blood plasma |
66 | increase | concentration of antagonist of interleukin-1 | Inflammation | immunoassay | blood plasma | |
67 | increase | concentration of tumor necrosis factor alpha | inflammation, tumor | Inflammation | immunoassay | blood plasma |
68 | increase | CMV IgG avidity | Aging | Immune aging | immunoassay | blood plasma |
69 | increase | Interleukin 2 | inflammation | Inflammation | immunoassay (U / ml) | blood plasma |
70 | increase | Interleukin 4 | inflammation | Inflammation | immunoassay (U / ml) | blood plasma |
71 | increase | Interleukin 6 | Aging | Inflammation | immunoassay (U / ml) | blood plasma |
72 | increase | Interleukin 10 | inflammation | Inflammation | immunoassay (U / ml) | blood plasma |
73 | increase | Interferon gamma | inflammation | Inflammation | immunoassay (U / ml) | blood plasma |
74 | increase | components of complement C3 | inflammation | Inflammation | Immunoturbidimetry (g / l) | blood serum |
75 | increase | components of the complement C4 | inflammation | Inflammation | Immunoturbidimetry (g / l) | blood serum |
76 | increase | Beta 2-microglobulin | inflammation, lymphoid tumors | levels of beta-2-microglobulin reflects the proliferation of lymphocytes and the intensity of cell turnover. | immunoassay | |
77 | increase | Glial fibrillary acidic protein | aging, neurodegeneration | enzyme multiplied immunoassay | blood serum | |
78 | decrease | Lon protease activity | Aging | enzyme multiplied immunoassay | ||
79 | decrease | Splitting vector Na, Ca, glutathione and glucose | Aging | immunoassay | ||
80 | increase | Phosphorylated tau protein | Alzheimer's disease | accumulates in Alzheimer's disease | immunoassay | spinal fluid |
81 | increase | Total tau protein | Alzheimer's disease | accumulates in Alzheimer's disease | immunoassay | spinal fluid |
82 | increase | ?-Amyloid | Alzheimer's disease, dementia with Lewy bodies | accumulates in amyloid plaques | PET-detection of plaques stained Pittsburgh compound B, immuno-assay, atomic force microscopy | NA |
83 | increase | Hantingtin | Huntington's chorea | accumulates in Huntington's disease | immunoassay | diseased tissue |
84 | increase | ?-Synuclein | Parkinson's disease, Alzheimer's disease, multiple system atrophy, dementia with Lewy bodies | accumulates in Parkinson's disease | immunoassay | diseased tissue |
85 | increase | progerin | aging, progeria | immunofluorescence | ||
86 | increase | cytoplasmic tubulin in the nucleus | Aging | |||
87 | decrease | Thioredoxin 1 | aging, cancer, liver cancer, lung | restores the disulfide bonds, antioxidant activity | ||
88 | decrease | Peroxiredoxin | Aging | protection of cells from oxidative stress and participate in the redox regulation of intracellular signaling. | ||
89 | decrease | Superoxide dismutase | aging, cardiovascular disease, diabetes, atherosclerosis | antioxidant properties | fotohemilyuminestsentsiya (U / g / Hb) | blood serum |
90 | increase | Active Cu, Zn-dependent supreoksiddismutazy | aging nephropathy, ischemic myocarditis, rheumatoid arthritis | fotohemilyuminestsentsiya | blood serum | |
91 | decrease | Glutathione | General | antioxidant properties | colorimetry | blood serum |
92 | decrease | glutathione peroxidase activity | General | kinetic (mol / L min) | blood serum | |
93 | decrease | alpha-glutathione S-transferase | liver function | antioxidant properties | kinetic (mol / L min) | blood serum |
94 | decrease | pi-glutathione S-transferase | liver function | antioxidant properties | kinetic (mol / L min) | blood serum |
95 | decrease | catalase | Potential aging | kinetic (mAbs / L) | blood plasma | |
96 | increase | concentration of 8-hydroxy-2-deoxyguanosine | Potential aging | destruction of DNA | ||
97 | increase | concentration of malondialdehyde | Potential aging | |||
98 | decrease | concentration of carotenoids | Potential aging | |||
99 | increase | concentration of caveolin-1 | Potential aging | |||
100 | increase | Pyridine | osteoporosis, primary hyperparathyroidism, osteomalacia, diseases of the joints, metastasis | high performance liquid chromatography | urine |